Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERO: Adjuvant Everolimus in Laryngotracheal Stenosis
NCT05153668Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Sep 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of everolimus in idiopathic subglottic stenosis (ISS), sponsored by Johns Hopkins University. Primary endpoint: Peak Expiratory Flow at 2 years. Started Sep 2022; status: completed.
02
Drugs
everolimus
03
Conditions
idiopathic subglottic stenosis (ISS)
Beyond the preview
Go deeper on NCT05153668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153668.